X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Pyramid Biosciences will develop and commercialize GQ1010, a potential best-in-class antibody drug conjugate (ADC) targeting TROP2, worldwide except for Greater China, using GeneQuantum's proprietary technology.
Lead Product(s): GQ1010
Therapeutic Area: Oncology Product Name: GQ1010
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: GeneQuantum Healthcare
Deal Size: $1,020.0 million Upfront Cash: $20.0 million
Deal Type: Licensing Agreement April 13, 2023
Details:
PBI-200 is an oral, highly potent, and selective inhibitor of TRK kinase that is currently in clinical development for the treatment of patients with cancers that harbor abnormalities involving the tropomyosin receptor kinases.
Lead Product(s): PBI-200
Therapeutic Area: Oncology Product Name: PBI-200
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2022
Details:
Molecular Intelligence Trials (MI Trials) collaboration will enhance identification of patients with NTRK fusion-positive solid tumors, including primary and metastatic CNS tumors potentially eligible for enrollment in the ongoing PBI-200-101 Phase 1/2 clinical study.
Lead Product(s): PBI-200
Therapeutic Area: Oncology Product Name: PBI-200
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Caris Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
